Business Wire

MINISTRY-OF-HAJJ-UMRAH

27.12.2022 13:16:42 CET | Business Wire | Press release

Share
Hajj Expo Slated for January 2023, under the Patronage of Makkah Governor

Under the patronage of H.R.H Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques and Governor of Makkah Region, the Ministry of Hajj and Umrah will be organizing the ‘Hajj Expo 2023’ conference and exhibition, on 9-12 January 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221227005098/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

His Royal Highness Prince Khaled Al-Faisal, Advisor to the Custodian of the Two Holy Mosques, Governor of Makkah Region (Photo: AETOSWire)

The four-day event is part of the Ministry's ongoing efforts to build an innovative ecosystem of services and solutions to better serve pilgrims at the Two Holy Mosques, while enhancing their religious and cultural experiences. It aims to create an integrated and sustainable ecosystem that improves pilgrims’ experiences, anticipate their future trends, and establish opportunities for further collaborations, agreements, and local and international initiatives.

H.E. Minister of Hajj and Umrah, Dr. Tawfiq bin Fawzan Al-Rabiah, said: “The conference will allow entrepreneurs, innovators, and researchers from more than 200 global organizations to share successful experiences, and brainstorm sustainable quality solutions designed to cater to pilgrims’ aspirations and needs. This reflects the unrelenting support dedicated by the Custodian of the Two Holy Mosques, and HH the Crown Prince to the Hajj and Umrah sector, in line with the Saudi Vision 2030.”

With delegations from over 56 countries, ‘Expo Hajj’ is expected to witness the signing of 400 agreements and partnerships. It will feature 10 keynote sessions, 13 panel discussions and ‘Hajj Talks’, as well as 36 workshops and related events and activities, notably the Islamic exposition and the ‘Hajj Hackathon’.

‘Hajj Expo 2023’ will be sponsored by several entities and companies, including Kidana Development Company, Elm, Al Wukalla Company, Catering Contractors Association, Muslim World League, Rua AlMadinah Holding, Motawifs Pilgrims for Southeast Asian Countries Co., Alrajhi Umrah, Dallah Albaraka Holding, Sadu Business Solutions, The Company for Cooperative Insurance (Tawuniya), and Saudi Arabia Railways (SAR), Saudi Public Transport Company (SAPTCO), Mohamed Yousuf Naghi Motors Co., Flynas, Saudi Al-Qaid Transportation Co., Alif Alif FM, High Point Technology Company, and Casablanca Company for Hotel & Touristic Services Co. LTD.

The 2021 edition of the conference saw record numbers with +45,000 attendees and 115 commercial agreements. The second edition will feature a wide range of scientific sessions, workshops, and training programs, with several ministers of Islamic affairs, endowments and Hajj ambassadors and consuls, and Hajj and Umrah operators from around the world.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221227005098/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release

In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release

IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye